DCGI Classifies 135 Ophthalmology Related Medical Devices Under MD Rules

New Delhi : The Drugs Controller General (India) has classified 135 medical devices related to ophthalmology under the provisions of Medical Devices Rules, 2017. In another notice, it has also classified 51 medical devices pertaining to respiratory treatments under the provisions of Medical Devices Rules, 2017, the rule formed to regulate them with respect to the import, manufacture, sale and distribution, and clinical investigation.

The drug regulator listed ophthalmology-related medical devices including automated lens meter (dioptometer), bagolini lens, blepharoplasty scissors, contact lens including coloured contact lens, corneal marker, corneal scissors, corneal shield, diagnostic condensing lens, donor cornea container, euthyscope, eye cup, eye muscle clamp, eye pad, eye spud, eyelid clamp, among others.

The DCGI, in in another notice, listed the medical devices including cerebral oximeter, bulk oxygen concentration system, cough long-term ambulatory recording system, dry powder inhaler, foetal pulse oximeter, oxygen concentrator, gas pipeline/supply system air compressor, hypopnea sensor and alarm, infant apnoea monitor, manual chest percussion, nitrogen monoxide analyser, steam inhaler, stress test treadmill, therapeutic positive pressure breathing ventilator, thoracic suction pump, among others under the Medical Devices Rules.

General intended use given against each of the devices is for guidance to the applicants intended to furnish application of import or manufacture of medical devices under the provisions of Medical Devices Rules, 2017. However, a device may have specific intended use as specified by its manufacturer.

The drug regulator has earlier classified 112 medical devices pertaining to anaesthesiology and around 208 medical devices in various categories including rehabilitation, physical support, dermatology and plastic surgery and interventional radiology and another 80 in vitro diagnostic medical devices including analysers, instruments and softwares, from mid July, 2021.

  • Related Posts

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states